Prognostic Significance of COVID-19 MSCT Chest Findings on Short Term Disease Progression
NCT ID: NCT05235373
Last Updated: 2022-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2020-04-01
2021-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of COVID-19 Infection and Disease Progression
NCT04484597
MSCT Chest in Suspected COVID-19 Patients
NCT04492865
Prediction of Clinical Course in COVID19 Patients
NCT04377685
COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising
NCT04433039
Early Identification and Severity Prediction of Acute Respiratory Infectious Disease
NCT04955756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria:
• Patients who had positive RT-PCR test for COVID-19 infection and show positive chest CT findings.
Exclusion criteria:
* Patients with negative RT PCR test for COVID 19 infection.
* Patients with positive RT PCR test for COVID 19 and negative chest CT findings.
* Patients with other pre-existing lung pathologies in the chest CT.
Data were collected from patients files included; history including symptoms and co-morbidities , and previously available examination data.
Approval was taken from the ethics committee of researchers of Benha university. An informed consent was taken from all the participants.
The consent contains:
1. Their approval that their studies and clinical data could be used for research purpose.
2. All patients' clinical data is considered confidential.
3. Signatures or fingerprints of the participants were taken. The picture archiving and communication systems (PACS) in both hospitals were revised during the period form the 1st of April 2020 to the 31st of December 2020. The included CT studies were revised first for technical appropriateness, and the studies with technical problems were excluded.
All chest CT examinations were performed using multislice CT equipment (Toshiba Activion 16 and Toshiba Alexion 16). The exams were performed with patients in supine position and breath-hold during full expiration. The scanning range was from the lower neck down to the level of the adrenal glands. The scanning parameters were as follows: helical scanning mode; tube voltage, 120 kV; tube current-time product, 50-350 mAs; pitch, 1.2 and 1.375; matrix, 512 × 512; slice thickness, 5 mm; reconstructed in distribution lung window; reconstructed slice thickness, 1.25 mm. Followed by sagittal and coronal reconstruction.
The technically accepted studies were extracted from the PACS system. They were interpreted by radiologists and pulmonologist (14 and 10 years in chest CT interpretation respectively) in blind manner.
The following CT features were assessed: (peripheral, central, or central and peripheral), number of lobes involved (one, two or three, four or five), shape (patchy, nodular), appearance (ground-glass opacity \[GGO\], consolidation, or GGO with consolidation), specific signs within the lesions (vascular thickening, crazy paving pattern, air bronchogram sign, halo sign, and fibrosis), size of largest lesion (\< 1 cm, 1-3 cm, \> 3 cm), and extra-pulmonary manifestations (mediastinal and hilar lymph node enlargement, pleural effusion, pleural thickening). CT severity scoring was calculated for each case (2).
The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive. According to the progression of the respiratory symptoms (dyspnea, respiratory rate and O2 saturation), the short-term clinical outcome of patients was classified into 4 groups, as follows:
1. Group A: (mild cases): with no progression of the respiratory symptoms.
2. Group B: (moderate cases): who have worsened disease but not requiring ICU admission.
3. Group C: (sever cases): patient who needed ICU admission.
4. Group D: (fatality cases): cases who died with or without ICU admission). Statistical Analysis Data were collected, revised, coded and entered to the Statistical Package for Social Science (IBM SPSS) version 20. The qualitative data were presented as number and percentages while quantitative data were presented as mean, standard deviations and ranges when their distribution found parametric. The comparison between two groups with qualitative data were done by using Chi-square test and/or Fisher exact test which was used instead of Chi-square test when the expected count in any cell was found less than 5. The comparison between more than two independent groups with quantitative data and parametric distribution was done by using One Way ANOVA Test. The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant as the following: P\> 0.05 = non-significant (NS), P \< 0.05 = significant (S), P \< 0.001 = highly significant (HS)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group A: (mild cases): with no progression of the respiratory symptoms.
multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
No interventions assigned to this group
group B: (moderate cases): who have worsened disease but not requiring ICU admission.
multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
No interventions assigned to this group
Group C: (sever cases): patient who needed ICU admission.
multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
No interventions assigned to this group
Group D: (fatality cases): cases who died with or without ICU admission).
multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with other pre-existing lung pathologies in the chest CT.
20 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AMIRA HUSSEIN ALLAM
assistant professor of chest diseases and tuberculosis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AMIRA HM Allam, MD
Role: PRINCIPAL_INVESTIGATOR
chest department, Faculty of medicine, Benha University, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha University hospital
Banhā, Kalyobia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TEJB-D-22-00019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.